ATEA PHARMACEUTICALS
Atea Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections. It caters to the healthcare industry and engages in the discovery and development of antiviral therapeutics that enable patients to have treatment for infections caused by RNA and DNA viruses. Atea Pharmaceuticals was established in 2014 and is headquartered in Boston, Massachusetts.
ATEA PHARMACEUTICALS
Industry:
Biopharma Biotechnology Health Care Pharmaceutical
Founded:
2014-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.ateapharma.com
Total Employee:
51+
Status:
Active
Total Funding:
283.43 M USD
Technology used in webpage:
Person Schema Gravatar Profiles Akamai Hosted
Similar Organizations
Aeovian Pharmaceuticals
Aeovian Pharmaceuticals aims to discover, develop, and commercialize therapeutics for the treatment of rare and age-related diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Fedora Pharmaceuticals
Fedora Pharmaceuticals engages in the discovery and development of antibiotics for life-threatening microbial drug resistance needs.
Idenix Pharmaceuticals
Idenix Pharmaceuticals is focused on the discovery and development of drugs for the treatment of human viral diseases.
Idera Pharmaceuticals
Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Bain Capital Life Sciences
Bain Capital Life Sciences investment in Series D - Atea Pharmaceuticals
Sectoral Asset Management
Sectoral Asset Management investment in Series D - Atea Pharmaceuticals
Ally Bridge Group
Ally Bridge Group investment in Series D - Atea Pharmaceuticals
Redmile Group
Redmile Group investment in Series D - Atea Pharmaceuticals
Morningside Venture Investments
Morningside Venture Investments investment in Series D - Atea Pharmaceuticals
Perceptive Advisors
Perceptive Advisors investment in Series D - Atea Pharmaceuticals
Rock Springs Capital
Rock Springs Capital investment in Series D - Atea Pharmaceuticals
T. Rowe Price
T. Rowe Price investment in Series D - Atea Pharmaceuticals
Cormorant Asset Management
Cormorant Asset Management investment in Series D - Atea Pharmaceuticals
Solasta Ventures
Solasta Ventures investment in Series D - Atea Pharmaceuticals
Key Employee Changes
| Date | New article |
|---|---|
| 2022-02-10 | Atea Pharmaceuticals Appoints Nancy Gail Berry Agrawal, Ph.D., as Executive Vice President of Preclinical Development |
Official Site Inspections
http://www.ateapharma.com Semrush global rank: 13.11 M Semrush visits lastest month: 78
- Host name: 104.26.10.50
- IP address: 104.26.10.50
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Atea Pharmaceuticals"
About Us - Atea Pharmaceuticals
Leveraging the power of our medicinal chemistry expertise and discovery capabilities, we are focused on discovering, optimizing, and rapidly advancing novel drug candidates that have the potential to meet unmet medical needs or …See details»
Our management team. - Our Team - Atea Pharmaceuticals
Atea is led by a team of highly experienced antiviral drug discoverers, developers and company builders, each bringing a unique perspective.See details»
Atea Pharmaceuticals - Crunchbase Company Profile
Atea Pharmaceuticals focuses on the discovery and development of next-generation therapeutics for severe human viral infections.See details»
Atea Pharmaceuticals, Inc | LinkedIn
Atea Pharmaceuticals, Inc Biotechnology Research Boston, Massachusetts 2,540 followers Discovery & development of breakthrough therapies for COVID-19 patients and severe viral diseasesSee details»
Atea Pharmaceuticals Provides Clinical and Corporate Update and …
Nov 11, 2021 The increase in general and administrative expenses was primarily due to the expansion of our organization and reflected an increase in payroll and personnel-related …See details»
Atea Pharmaceuticals - Craft
Aug 20, 2024 Atea Pharmaceuticals has 5 employees across 2 locations and $351.37 m in annual revenue in FY 2021. See insights on Atea Pharmaceuticals including office locations, …See details»
Atea Pharmaceuticals Reports First Quarter 2022 Financial Results …
May 10, 2022 The increase in research and development expenses was primarily due to the expansion of our organization and reflected an increase in payroll and personnel-related …See details»
Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation …
BOSTON, April 25, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and …See details»
Atea Pharmaceuticals to Present and Provide a Business Update at …
3 days ago For more information, please visit www.ateapharma.com. Forward-Looking Statements. This press release includes “forward-looking statements” within the meaning of …See details»
Contact Us - Atea Pharmaceuticals
BREAKING NEWS Atea Pharmaceuticals announces strategic collaboration with Roche to develop and commercialize AT-527 for patients with COVID-19.See details»
Atea Pharmaceuticals Provides Clinical and Corporate Update and …
Aug 12, 2021 New Data in Healthy Volunteers Confirmed that AT-527’s Active Metabolite Achieved Target Antiviral Levels in Lungs, Key Site of COVID-19 Infection AT-527 Phase 2 …See details»
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2021 ...
Feb 28, 2022 The increase in general and administrative expenses was primarily due to the expansion of the Company’s organization and reflected an increase in payroll and personnel …See details»
Careers - Atea Pharmaceuticals
All official Atea emails sent to potential candidates will come from the domain @ateapharma.com. If you have been defrauded or suspect identity theft as a result of an employment scam, …See details»
News Release - ir.ateapharma.com
Aug 8, 2022 The increase in general and administrative expenses was primarily due to the expansion of our organization. Interest Income and Other, Net: Interest income and other, ...See details»
Atea Pharmaceuticals Strengthens Management Team with …
Aug 24, 2020 Executive Vice President of Clinical Sciences and Vice President of Regulatory Bring Decades of Clinical and Regulatory Experience BOSTON, Mass., August 24, 2020 – …See details»
Atea Pharmaceuticals Reports Positive Proof of Concept
Apr 12, 2018 According to the World Health Organization, over 70 million people suffer from chronic hepatitis C. Direct-acting antiviral agents (DAAs) have markedly improved the …See details»
News Release - Atea Pharmaceuticals, Inc.
Sep 26, 2022 The World Health Organization has called dengue the most important mosquito-borne viral disease in the world. The FDA, together with other governmental and non …See details»
News - Atea Pharmaceuticals
Atea Pharmaceuticals Announces Strategic Collaboration with Roche to Develop and Distribute AT-527 for Patients with COVID-19. Roche Obtains Exclusive Right to Develop and Distribute …See details»
News Release - Atea Pharmaceuticals, Inc.
Aug 24, 2021 In vitro and in vivo data demonstrate favorable safety and potency against multiple dengue virus serotypes supporting ongoing clinical development of AT-752 Dengue is the …See details»